FY2019 Earnings Forecast for Blueprint Medicines Corp (NASDAQ:BPMC) Issued By Jefferies Financial Group

Blueprint Medicines Corp (NASDAQ:BPMC) – Stock analysts at Jefferies Financial Group issued their FY2019 earnings per share estimates for shares of Blueprint Medicines in a note issued to investors on Tuesday, November 5th. Jefferies Financial Group analyst E. Yang expects that the biotechnology company will post earnings per share of ($7.48) for the year. Jefferies Financial Group also issued estimates for Blueprint Medicines’ Q4 2019 earnings at ($1.54) EPS, Q1 2020 earnings at ($2.07) EPS, Q2 2020 earnings at ($2.19) EPS, Q3 2020 earnings at ($2.23) EPS, Q4 2020 earnings at ($2.56) EPS, FY2020 earnings at ($9.07) EPS, FY2021 earnings at ($7.67) EPS, FY2022 earnings at ($4.87) EPS and FY2023 earnings at ($1.07) EPS.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.19) by $0.26. Blueprint Medicines had a negative net margin of 2,258.84% and a negative return on equity of 80.02%. The firm had revenue of $9.14 million for the quarter, compared to the consensus estimate of $2.85 million. During the same quarter in the previous year, the firm earned ($1.66) EPS. The company’s quarterly revenue was up 734.6% compared to the same quarter last year.

Several other equities analysts have also recently issued reports on BPMC. Zacks Investment Research cut shares of Blueprint Medicines from a “buy” rating to a “sell” rating and set a $94.00 target price for the company. in a research note on Wednesday, August 7th. Morgan Stanley decreased their target price on shares of Blueprint Medicines from $109.00 to $108.00 and set an “overweight” rating for the company in a research note on Wednesday. JMP Securities began coverage on shares of Blueprint Medicines in a research note on Tuesday, October 22nd. They issued an “outperform” rating and a $106.00 target price for the company. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Monday, September 30th. Finally, Canaccord Genuity boosted their target price on shares of Blueprint Medicines from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Blueprint Medicines currently has an average rating of “Buy” and a consensus target price of $104.36.

Shares of Blueprint Medicines stock opened at $73.26 on Friday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 0.16. Blueprint Medicines has a 52-week low of $44.58 and a 52-week high of $102.98. The firm’s 50 day moving average price is $73.99 and its 200-day moving average price is $82.91. The company has a market cap of $3.46 billion, a P/E ratio of -13.59 and a beta of 1.60.

In related news, insider Ariel Hurley sold 415 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $84.02, for a total value of $34,868.30. Following the completion of the transaction, the insider now directly owns 415 shares in the company, valued at approximately $34,868.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anthony L. Boral sold 10,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $80.07, for a total transaction of $800,700.00. Following the completion of the sale, the insider now directly owns 1,300 shares of the company’s stock, valued at approximately $104,091. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,340 shares of company stock valued at $3,365,796. Company insiders own 4.02% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. increased its holdings in Blueprint Medicines by 62.8% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 423 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in Blueprint Medicines by 2.1% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 24,831 shares of the biotechnology company’s stock worth $2,342,000 after acquiring an additional 510 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Blueprint Medicines by 21.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,906 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 521 shares in the last quarter. Whittier Trust Co. increased its holdings in Blueprint Medicines by 58.1% in the 3rd quarter. Whittier Trust Co. now owns 1,632 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 600 shares in the last quarter. Finally, Tocqueville Asset Management L.P. increased its holdings in Blueprint Medicines by 9.1% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 7,830 shares of the biotechnology company’s stock worth $575,000 after acquiring an additional 650 shares in the last quarter. 99.39% of the stock is owned by institutional investors.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

See Also: Why are analyst ratings important in trading stocks?

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.